Sentence examples for mutations are preferentially from inspiring English sources

However, few alterations are caused by a transposition event because deleterious mutations are preferentially eliminated.

In particular, RGYW/WRCY motif mutations are preferentially targeted by T cell-dependent signals including CD40-CD40 linteractionsctions [ 41].

Homology-based 3D structure modeling reveals that the novel mutations are preferentially located at the protein surface and do not interfere with the active site.

Previous studies have demonstrated that K- ras codon 12 mutations are preferentially associated with polypoid growth of colorectal cancer; however, little is known about the molecular mechanism that determines ulcerative growth of colorectal cancer.

Thus, it appears that GNAQ mutations are preferentially present in a group of non-epithelium-related melanocytic lesions, sharing histological features and occurring in an anatomical distribution indicating a possible role of GNAQ in migration of melanocytes early during embryonic development.

These mutations are preferentially found in women, east Asians, never smokers and adenocarcinomas, often with a bronchioloalveolar histology (Fukuoka et al, 2003; Kris et al, 2003; Lynch et al, 2004; Miller et al, 2004; Paez et al, 2004; Perez-Soler et al, 2004; Eberhard et al, 2005; Shepherd et al, 2005; Tsao et al, 2005).

Missense mutations were preferentially localised to the phosphor-tyrosine kinase (Pkinase_Tyr) and eight resulted in an amino acid substitution from leucine to arginine at position 858 (L858R) (Network 2014; Zheng et al. 2016).

Since we detected no significant difference in p53 expression among the samples examined in this study, we explored the possibility that p53 LOF (loss-of-function) mutations were preferentially associated with the C-L group.

This type of mutations was preferentially clustered in the last MLK3 domain (P/S/T-rich).

In our study, GNAQ mutations were preferentially present in the melanocytomas, while the intermediate melanocytomas and melanomas were only infrequently mutated.

In BTC, a 13-15% tyrosine kinase domain mutation rate has been reported and it has been suggested that patients with tumor associated EGFR mutations be preferentially enrolled in clinical trials of EGFR-TKIs [ 17, 18].